Cargando…

The “4 plus 2” rituximab protocol makes maintenance treatment unneeded in patients with refractory ANCA-associated vasculitis: A 10 years observation study

BACKGROUND: ANCA associated vasculitides (AAV) often present with a chronic relapsing course. Relapse leads to increased immunosuppressive exposure and consequent toxicity. While two randomized controlled trials have shown rituximab (RTX) to be the most effective induction treatment in patients with...

Descripción completa

Detalles Bibliográficos
Autores principales:	Roccatello, Dario, Sciascia, Savino, Rossi, Daniela, Alpa, Mirella, Naretto, Carla, Radin, Massimo, Fenoglio, Roberta, Baldovino, Simone, Menegatti, Elisa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper: Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5581013/ https://www.ncbi.nlm.nih.gov/pubmed/28881714 http://dx.doi.org/10.18632/oncotarget.18120

Ejemplares similares

Non HCV-Related Mixed Cryoglobulinemic Vasculitis With Biopsy-Proven Renal Involvement: The Effects of Rituximab
por: Fenoglio, Roberta, et al.
Publicado: (2022)

Renal involvement as a unique manifestation of hemophagocytic syndrome
por: Roccatello, Dario, et al.
Publicado: (2022)

The challenge of treating hepatitis C virus-associated cryoglobulinemic vasculitis in the era of anti-CD20 monoclonal antibodies and direct antiviral agents
por: Roccatello, Dario, et al.
Publicado: (2017)

Vedolizumab for the Management of Refractory Behçet’s Disease: From a Case Report to New Pieces of Mosaic in a Complex Disease
por: Arbrile, Marta, et al.
Publicado: (2021)

A Prospective Study on Long-Term Clinical Outcomes of Patients With Lupus Nephritis Treated With an Intensified B-Cell Depletion Protocol Without Maintenance Therapy
por: Roccatello, Dario, et al.
Publicado: (2021)

Daratumumab Monotherapy in Severe Patients with AL Amyloidosis and Biopsy-Proven Renal Involvement: A Real Life Experience
por: Roccatello, Dario, et al.
Publicado: (2020)

Treating Patients With ANCA-Associated Vasculitis and Very Severe Renal Injury With an Intensified B Cell Depletion Therapy: Comparison With a Control Cohort Receiving a Conventional Therapy
por: Roccatello, Dario, et al.
Publicado: (2022)

Outpatient percutaneous native renal biopsy: safety profile in a large monocentric cohort
por: Roccatello, Dario, et al.
Publicado: (2017)

Dickkopf Homolog 3 (DKK3) as a Prognostic Marker in Lupus Nephritis: A Prospective Monocentric Experience
por: Sciascia, Savino, et al.
Publicado: (2022)

Safety and efficacy of pre-exposure prophylaxis with tixagevimab/cilgavimab (Evusheld) in patients with glomerular diseases who received rituximab
por: Sciascia, Savino, et al.
Publicado: (2023)

CD38 and Anti-CD38 Monoclonal Antibodies in AL Amyloidosis: Targeting Plasma Cells and beyond
por: Roccatello, Dario, et al.
Publicado: (2020)

Rituximab as a front-line therapy for adult-onset minimal change disease with nephrotic syndrome
por: Fenoglio, Roberta, et al.
Publicado: (2018)

Thrombotic risk assessment in antiphospholipid syndrome: the role of new antibody specificities and thrombin generation assay
por: Sciascia, Savino, et al.
Publicado: (2016)

The steroid-sparing effects of a mycophenolate mofetil-based regimen in the management of immunoglobulin A nephropathy in patients with histologically active lesions: A comparison with a control cohort receiving conventional therapy
por: Roccatello, Dario, et al.
Publicado: (2023)

Canakinumab as rescue therapy in familial Mediterranean fever refractory to conventional treatment
por: Alpa, Mirella, et al.
Publicado: (2015)

Daratumumab monotherapy for refractory lupus nephritis
por: Roccatello, Dario, et al.
Publicado: (2023)

A Case of Rituximab Use as an Induction and Maintenance of Remission in ANCA-Associated Vasculitis
por: Awad, Neveen, et al.
Publicado: (2016)

Rituximab Induction and Maintenance in ANCA-Associated Vasculitis: State of the Art and Future Perspectives
por: Treppo, Elena, et al.
Publicado: (2021)

Focal segmental glomerular sclerosis can be effectively treated using an intensive B-cell depletion therapy
por: Roccatello, Dario, et al.
Publicado: (2022)

Long-term maintenance rituximab for ANCA-associated vasculitis: relapse and infection prediction models
por: McClure, Mark E, et al.
Publicado: (2020)

Chasing the Zebra: a case of membranous-like Glomerulopathy with SSA/RO52 deposits and no overt connective tissue disease
por: Sciascia, Savino, et al.
Publicado: (2023)

Recognizing the new disorder “idiopathic hypocryoglobulinaemia” in patients with previously unidentified clinical conditions
por: Roccatello, Dario, et al.
Publicado: (2022)

Rituximab 500 mg 6-monthly infusions is an option in maintenance therapy of ANCA-associated vasculitis
por: Goel, Ruchika, et al.
Publicado: (2021)

Safety and tolerability of mRNA COVID-19 vaccines in people with antiphospholipid antibodies
por: Sciascia, Savino, et al.
Publicado: (2021)

PR3-ANCAs predict relapses in ANCA-associated vasculitis patients after rituximab
por: van Dam, Laura S, et al.
Publicado: (2020)

Severe Multi-Organ Failure and Hypereosinophilia: When to Call It “Idiopathic”?
por: Radin, Massimo, et al.
Publicado: (2018)

PReS-FINAL-2311: Rituximab in paediatric ANCA-associated vasculitis
por: Mestrallet, G, et al.
Publicado: (2013)

Combination Therapy With Rituximab and Cyclophosphamide for Remission Induction in ANCA Vasculitis
por: Cortazar, Frank B., et al.
Publicado: (2017)

Genetic Factors in Antiphospholipid Syndrome: Preliminary Experience with Whole Exome Sequencing
por: Barinotti, Alice, et al.
Publicado: (2020)

Cerebrovascular events in patients with isolated anti-phosphatidyl-serine/prothrombin antibodies
por: Radin, Massimo, et al.
Publicado: (2021)

Genetic Factors Associated with Rheumatoid Arthritis and Systemic Vasculitis: Evaluation of a Panel of Polymorphisms
por: Menegatti, Elisa, et al.
Publicado: (2009)

Daratumumab for the treatment of refractory ANCA-associated vasculitis
por: Ostendorf, Lennard, et al.
Publicado: (2023)

Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis
por: Smith, Rona M, et al.
Publicado: (2020)

The Efficacy and Safety of Rituximab in ANCA-Associated Vasculitis: A Systematic Review
por: Habibi, Mohammad Amin, et al.
Publicado: (2022)

Rituximab-associated hypogammaglobulinemia in ANCA-associated vasculitis: Incidence and time course
por: Tariq, Anam, et al.
Publicado: (2022)

Rituximab versus azathioprine for maintenance of remission for patients with ANCA-associated vasculitis and relapsing disease: an international randomised controlled trial
por: Smith, Rona M, et al.
Publicado: (2023)

13. CMV Reactivation in refractory ANCA-associated vasculitis
por: Hassan, Neelam, et al.
Publicado: (2019)

Reliability of Lupus Anticoagulant and Anti-phosphatidylserine/prothrombin Autoantibodies in Antiphospholipid Syndrome: A Multicenter Study
por: Sciascia, Savino, et al.
Publicado: (2019)

Recent advances in the management of systemic lupus erythematosus
por: Sciascia, Savino, et al.
Publicado: (2018)

Membranous Nephropathy with Proteinase 3-ANCA-associated Vasculitis Successfully Treated with Rituximab
por: Yoshida, Shun, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_rn9dm1js7m527j91e18kcts5cq